Histostem Participates In Successful Stem Cell Treatment For Acute Spinal Cord Injury In Dogs
/* 468x60, */
Stem Cell Therapy International, Inc. (OTCBB: SCII) announced that Histostem Ltd. of South Korea ("Histostem") has participated in a study resulting in the successful treatment of spinal cord injury in dogs through the use of Multipotent Stem Cells (MSCs) derived from Human Umbilical Cord Blood (HUCB). The study, a collaborative effort between a team of doctors from the Departments of Veterinary Surgery and Veterinary Anatomy at Konkuk University, Seoul, Korea and Dr. Hoon Han, President and Founder of Histostem, presented a method for the percutaneous transplantation of stem cells and investigated the therapeutic efficacy of transplanting stem cells to improve the recovery of the central nervous system following such acute spinal cord injury.
While previous research on spinal cord injury has typically used rats, this study used dogs which have a spinal cord structure more similar to humans. Within the test group, those dogs that received cellular transplants exhibited gradual improvement in hind limb locomotion two to three weeks after the transplant and also demonstrated reduced cyst and injury size.
Dr. Han commented, "Our research demonstrated a new, less invasive method of transplanting human umbilical cord blood derived multipotent stem cells, which avoids surgical exposure and allows the cells to be more precisely transplanted into the spinal cord. In addition to this breakthrough in the technique used to transplant stem cells, we also had success in improving the condition of the spinal cord injury among the test group. Based on the successful results of this study and because of the canine spinal cord's resemblance to a human spinal cord, we are optimistic that this technique has many potential applications in the treatment of human spinal cord injury through stem cell transplantation."
More details on the research process and results are available in the December 2009 issue of the Journal of Neurosurgery: Spine.
About Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of regenerative medicine. SCII (soon to be renamed AmStem Corporation) is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.
About AmStem International Inc.
Amstem International Inc. ("AmStem") is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Its web site is under construction at http://www.amsteminc.com.
Histostem Co. Ltd.
/* 468x60, */
Last relative articles:
- 2010 National Evacuation Conference
- Dogs May Provide An Excellent Model For Understanding Human Complex Diseases
- AVMA Seeks Member Input To Shape Strategic Plan
- BVA And BSAVA Welcome Scotland's Move To Control Dangerous Dogs
- BioCurex Announces Commercialization Of OncoPet RECAFTM, The First Blood Test For Cancer Detection In Companion Animals
- BTV8: Still Out - Let's Keep It Out, UK
- BVA Warns Against Kneejerk Reaction To TB Report, UK
- Wide Variation In Calorie Content Among Low Calorie Pet Foods
- AVMA Calls For Stronger Animal Disease Traceability System
- Bioniche E. Coli O157 Vaccine Recognized In Prestigious Scientific Journal
stem, stem cell, stem cells, successful stem, multipotent stem, transplanting stem, dogs stem, inc stem, transplantation stem, injury stem